CorMedix Slides on Preliminary FY25 Results, FY26 Revenue Guidance

Dow Jones01-09

By Emon Reiser

Shares for CorMedix fell after the biopharmaceutical company guided for a potential decline in revenue in 2026.

The stock was down 35%, at $7.26, midday Thursday, on pace for its worst percentage decrease since March 2025.

CorMedix on Thursday guided for revenue between $300 million and $320 million for fiscal 2026, compared with $310 million in net revenue for fiscal 2025, according to the company's unaudited preliminary results. Analysts polled FactSet expected $312.9 million for fiscal 2025 and $423.3 million for 2026.

The Berkeley Heights, N.J., company said it expects the level of reimbursement to institutions treating dialysis patients to significantly decline on July 1, as calculated by the Centers for Medicare & Medicaid Services. The new math would lead to a reduction in net pricing for the company's catheter lock, DefenCath, in the third and fourth quarters.

"If CMS utilizes the same methodology to calculate" an add-on adjustment for DefenCath after Jan. 1, 2027, the company expects higher DefenCath sales prices next year compared with the second half of 2026.

Write to Emon Reiser at emon.reiser@wsj.com

(END) Dow Jones Newswires

January 08, 2026 12:07 ET (17:07 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602399794?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 01:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602399794","market":"us","top_or_hot":-1,"title":"CorMedix Slides on Preliminary FY25 Results, FY26 Revenue Guidance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Emon Reiser \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares for CorMedix fell after the biopharmaceutical company guided for a potential decline in revenue in 2026. \n</p>\n<p>\n  The stock was down 35%, at $7.26, midday Thursday, on pace for its worst percentage decrease since March 2025. \n</p>\n<p>\n  CorMedix on Thursday guided for revenue between $300 million and $320 million for fiscal 2026, compared with $310 million in net revenue for fiscal 2025, according to the company's unaudited preliminary results. Analysts polled FactSet expected $312.9 million for fiscal 2025 and $423.3 million for 2026. \n</p>\n<p>\n  The Berkeley Heights, N.J., company said it expects the level of reimbursement to institutions treating dialysis patients to significantly decline on July 1, as calculated by the Centers for Medicare &amp; Medicaid Services. The new math would lead to a reduction in net pricing for the company's catheter lock, DefenCath, in the third and fourth quarters. \n</p>\n<p>\n  \"If CMS utilizes the same methodology to calculate\" an add-on adjustment for DefenCath after Jan. 1, 2027, the company expects higher DefenCath sales prices next year compared with the second half of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Emon Reiser at emon.reiser@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 12:07 ET (17:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Slides on Preliminary FY25 Results, FY26 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Slides on Preliminary FY25 Results, FY26 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-09 01:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Emon Reiser \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares for CorMedix fell after the biopharmaceutical company guided for a potential decline in revenue in 2026. \n</p>\n<p>\n  The stock was down 35%, at $7.26, midday Thursday, on pace for its worst percentage decrease since March 2025. \n</p>\n<p>\n  CorMedix on Thursday guided for revenue between $300 million and $320 million for fiscal 2026, compared with $310 million in net revenue for fiscal 2025, according to the company's unaudited preliminary results. Analysts polled FactSet expected $312.9 million for fiscal 2025 and $423.3 million for 2026. \n</p>\n<p>\n  The Berkeley Heights, N.J., company said it expects the level of reimbursement to institutions treating dialysis patients to significantly decline on July 1, as calculated by the Centers for Medicare &amp; Medicaid Services. The new math would lead to a reduction in net pricing for the company's catheter lock, DefenCath, in the third and fourth quarters. \n</p>\n<p>\n  \"If CMS utilizes the same methodology to calculate\" an add-on adjustment for DefenCath after Jan. 1, 2027, the company expects higher DefenCath sales prices next year compared with the second half of 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Emon Reiser at emon.reiser@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 12:07 ET (17:07 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602399794","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602399794","pubTimestamp":1767892020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares for CorMedix fell after the biopharmaceutical company guided for a potential decline in revenue in 2026.The stock was down 35%, at $7.26, midday Thursday, on pace for its worst percentage decrease since March 2025.CorMedix on Thursday guided for revenue between $300 million and $320 million for fiscal 2026, compared with $310 million in net revenue for fiscal 2025, according to the company's unaudited preliminary results. Analysts polled FactSet expected $312.9 million for fiscal 2025 and $423.3 million for 2026.The Berkeley Heights, N.J., company said it expects the level of reimbursement to institutions treating dialysis patients to significantly decline on July 1, as calculated by the Centers for Medicare & Medicaid Services. The new math would lead to a reduction in net pricing for the company's catheter lock, DefenCath, in the third and fourth quarters.\"If CMS utilizes the same methodology to calculate\" an add-on adjustment for DefenCath after Jan. 1, 2027, the company expe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CRMD":"CorMedix Inc."},"translate_title":"CorMedix在25财年初步业绩和26财年收入指引上下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"By Emon Reiser \n\n\n \n\n\n  Shares for CorMedix fell after the biopharmaceutical company guided for a potential decline in revenue in 2026. \n\n\n  The stock was down 35%, at $7.26, midday Thursday, on pace for its worst percentage decrease since March 2025. \n\n\n  CorMedix on Thursday guided for revenue between $300 million and $320 million for fiscal 2026, compared with $310 million in net revenue for fiscal 2025, according to the company's unaudited preliminary results. Analysts polled FactSet expected $312.9 million for fiscal 2025 and $423.3 million for 2026. \n\n\n  The Berkeley Heights, N.J., company said it expects the level of reimbursement to institutions treating dialysis patients to significantly decline on July 1, as calculated by the Centers for Medicare & Medicaid Services. The new math would lead to a reduction in net pricing for the company's catheter lock, DefenCath, in the third and fourth quarters. \n\n\n  \"If CMS utilizes the same methodology to calculate\" an add-on adjustment for DefenCath after Jan. 1, 2027, the company expects higher DefenCath sales prices next year compared with the second half of 2026. \n\n\n \n\n\n  Write to Emon Reiser at emon.reiser@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 12:07 ET (17:07 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602399794","isCrawlerRequest":true}